ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Shionogi set to begin COVID vaccine Phase 3 trial in Vietnam

Japanese drugmaker aims to make vaccine available domestically early next year

Shionogi CEO Isao Teshirogi said a clinical trial aims to put its "recombinant protein vaccine" on the list of the World Health Organization-approved vaccines. (Source photos by Atsushi Ooka and Jiji) 

TOKYO -- Japanese drugmaker Shionogi will begin a Phase 3 clinical trial on its COVID-19 vaccine this month, mainly in Vietnam and other Asian countries, CEO Isao Teshirogi said Monday.

The clinical trial, which will involve two groups, one given the actual vaccine and the other given a placebo, is aimed at putting its "recombinant protein vaccine" on the list of the World Health Organization-approved vaccines, Teshirogi said at a news conference to discuss the company's earnings. Shionogi is the front-runner in COVID vaccine development in Japan,

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more